PTT-4256

DRUG2 trials

Sponsors

Pathios Therapeutics Limited, Pathios Therapeutics Pty Ltd

Conditions

Advanced Solid TumorSolid Tumours

Phase 1

An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).

RecruitingNCT06634849

Pathios Therapeutics Pty LtdAdvanced Solid Tumor

Start: 2024-11-04End: 2027-10-30Target: 30Updated: 2026-02-10

A Modular, Open Label, Dose Finding Phase 1/2 Clinical Trial in Patients with Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PTT-4256 (RAISIC-1: Relief of Acidic Immune Suppression In Cancer)

Not yet recruitingCTIS2025-522944-41-00

Pathios Therapeutics LimitedSolid Tumours

Target: 25Updated: 2026-02-27

Related Papers

64 GPR65 is a Novel Therapeutic Target Associated with Immune Exhaustion in Clear Cell Renal Cell Carcinoma

The Oncologist2026-09-01

RAISIC-1: A phase 1/2 clinical trial of the GPR65 inhibitor PTT-4256—Preliminary safety, tolerability, pharmacokinetic, and pharmacodynamic results.

Journal of Clinical Oncology2026-05-27

Low pH, High Stakes: A Narrative Review Exploring the Acid-Sensing GPR65 Pathway as a Novel Approach in Renal Cell Carcinoma.

2025-12-04